Novavax Inc. announced on Monday that it has begun enrolling pediatric participants in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine).
The study will be conducted on 150 healthy Canadian children ranging in age from 2 to 6 and is the first study of this potential vaccine to be done using children.
“Today’s announcement of the initiation of the Phase 1 RSV F Vaccine pediatric trial delivers on our stated goal of starting RSV F Vaccine trials in all three of our target populations during the third and fourth quarters of 2014,” Stanley C. Erck, president and CEO of the biopharmaceutical company, said. “With the initiation of clinical trials in pregnant women, elderly subjects and children, we position our RSV F Vaccine franchise to deliver important clinical results in the second and third quarter of 2015.”
RSV causes respiratory infection and is mostly seen in young children and the elderly.
“RSV is a significant cause of pediatric respiratory disease, including pneumonia, bronchiolitis and recurrent wheezing,” Dr. Gregory Glenn, senior vice president of research and development at Novavax, said. “The ability to prevent RSV-related lower respiratory disease in the pediatric population via immunization is an important public health goal. We believe this clinical trial is an important step forward in addressing that goal.”